BRT Biotechnologies

Your partner of choice for small molecule drug discovery

Learn More

About Us

BRT Biotechnologies is aiming to drug the undruggable. Our proprietary platform allows for ultra-high-throughput synthesis of large and diverse small molecule libraries that can be directly screened for activity. Our synthetic approach uses no tags and no barcodes and our libraries are ready for your phenotypic or target-based drug discovery screen.


We believe our technology - which combines ultra-high-throughput synthesis with activity-based screens - will maximize success in early stage drug discovery.

Jane Liu, CEO

Expertise in biochemical screens and selections. Successful in securing funding and team management.

Greg Copeland, CSO

Expertise in solid-phase chemistry, library synthesis, and microfluidics.


Have any questions?

Contact Us.

BRT Biotechnologies
Claremont, CA 91711